ACHV

Achieve Life Sciences, Inc.

Healthcare
Biotechnology
$725M market cap

Forecast run · Sep 14, 2026Upside rank 456 of 3,136

Model Signal

ForecastQ Daily Probabilities

56.7%

36.2%

33.8%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$7.06

Price target$14.00

Implied move+98.3%

Analysts6

ForecastQ Portfolios

ACHV is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.